Viking Therapeutics received two positive analyst calls on Thursday. Barclays upgraded the stock to Strong Buy, while UBS Group initiated coverage with a Buy rating.
Analysts have a Moderate Buy consensus rating. Their average price target is $99.44.
The calls follow Viking’s October 14 announcement that it had launched the SUNRISE Phase 3 clinical program for oral VK2735, an obesity drug candidate.
The stock opened at $25.47 on Thursday. Institutional investors hold 76.03% of the company’s shares.